Containment Cosmetics Marketing Packaging 
FDA Law Blog
MARCH 21, 2024
As readers of our blog know, MoCRA was a significant change to regulation of cosmetics. As the new law unfolds—and as state laws regarding ingredients and packaging, as well as laws regarding environmental claims continue to affect the cosmetics and personal care industries—the topics covered at the conference have never been more relevant.
XTalks
APRIL 26, 2021
The marker may soon be found on food and beverage products, pet food, dietary supplements, cosmetics and more. Future Market Insights predicted in 2019, prior to the onset of the COVID-19 pandemic, that the upcycled food industry was worth more than $46 billion, with an estimated compound annual growth rate (CAGR) of five percent.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
APRIL 14, 2021
The US Food and Drug Administration (FDA) defines color additives as “any substance that imparts color to a food, drug, cosmetic, or the human body. These labels must be present on the packaging of the items sold. They are also found in beverages such as sports drinks and beauty products such as mouthwash and shampoo.
Pfizer
DECEMBER 13, 2022
One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. The information contained in this statement is as of December 13, 2022. For more information, please visit www.PAXLOVID.com. . Disclosure Notice.
FDA Law Blog
JUNE 12, 2023
The Federal Food, Drug, and Cosmetic Act (FDC Act) requires that all animal foods, like human foods, be safe to eat, produced under sanitary conditions, contain no harmful substances, and be truthfully labeled. By Riëtte van Laack — FDA regulates pet food similar to other animal foods.
Pfizer
DECEMBER 20, 2022
One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. The information contained in this statement is as of December 20, 2022. For more information, please visit www.PAXLOVID.com. Disclosure Notice.
FDA Law Blog
FEBRUARY 15, 2022
A meeting that is necessary to address an important safety issue that needs immediate action when the meeting requester learns about a safety issue related to an OTC monograph drug that is marketed or being developed. By Deborah L. An OMOR submission when a meeting requester has an interest in initiating an OMOR (i.e.,
Expert insights. Personalized for you.
64 
Let's personalize your content